Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity*

• DOI: 10.1111/bjd.20588
• Publication Date: 2021-06-17T07:01:00Z
• Authors: E. Papadavid; E. Kapniari; V. Pappa; V. Nikolaou; T. Iliakis; M. Dalamaga; C. Jonak; S. Porkert; S. Engelina; P. Quaglino; P.L. Ortiz‐Romero; C. Vico; A. Cozzio; F. Dimitriou; R. Guiron; E. Guenova; E. Hodak; M. Bagot; J. Scarisbrick
• Keywords: Brentuximab vedotin; Interquartile range; Peripheral T-cell lymphoma

Brentuximab vedotin (BV) was approved as a therapy for mycosis fungoides (MF) based on the ALCANZA trial. Little real-world data, however, are available.To evaluate efficacy and safety of BV in patients with MF/Sézary Syndrome (SS) variable CD30 positivity cohort to explore potential predictors response.Data from 72 MF/SS across nine EORTC (European Organization Research Treatment Cancer) centres were included. The primary endpoint proportion with: overall response (ORR), ORR lasting over 4 months (ORR4), time (TTR), duration (RD), progression-free survival (PFS) next treatment (TTNT). Secondary aims included evaluation association clinicopathological features ORR, RD TTNT.All had received at least one systemic treatment. achieved 45 67; ORR4 28 67 median TTR 8 weeks [interquartile range (IQR) 5·5-14] 9 (IQR 3·4-14). Median PFS 7 2-12) TTNT 30 days (6-157·5). Patient response, RD, not associated any characteristics. In MF group, stage IIB/III vs. IV longer higher percentage ORR4. There statistically significant between large-cell transformation skin (P = 0·03). more frequently without lymph node involvement 0·04).BV is an effective option MF/SS, including those positivity, transformation, SS, disease who have been treated previously several therapies.